Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Rituximab in Waldenstrom's Macroglobulinemia
NCT00492050Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2006
- Primary completion
- Feb 2021
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in Waldenström macroglobulinemia (WM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Response Rate After 2 Cycles of Treatment With Bortezomib and Rituximab at 10 weeks, Response Rate After 3 Cycles of Treatment With Bortezomib and Rituximab at 15 weeks and 1 more. Started Aug 2006; status: active, not recruiting.
02
Drugs
bortezomib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00492050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492050.